Trial site
Moffit Cancer Center
Tampa, Florida 33612, United StatesNot linked to an institution yet
- 18running trials
- 1closed trial
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 17 trials
- Phase 1/22 trials
- Phase 21 trial
- Status
- Recruiting8 trials
- Active, not recruiting5 trials
- Not yet recruiting5 trials
- Completed1 trial
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Celyad Oncology SA2 trials
- Institut de Recherches Internationales Servier2 trials
- BioNTech SE1 trial
- CG Oncology, Inc.1 trial
- and 10 more
Running trials
Not yet recruiting
Modifying Diet to Improve Gut Microbiome
NCT03924778· H. Lee Moffitt Cancer Center and Research Institute· Source
Contact: Tiffany Carson, PhD
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Contact: Andrew Kuykendall (principal investigator)
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07219212· Phase 1· Johnson & Johnson Enterprise Innovation Inc.· Source
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190· Phase 3· IDEAYA Biosciences· Source
Contact: Nikhil Khushalani, MD, Principal Investigator
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704· Phase 3· SOFIE· Source
Contact: Jacqueline Guillermo Adams
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· Phase 3· ImmunityBio, Inc.· Source
Contact: Erika Gonzalez
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· Phase 1/2· BioNTech SE· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157· Phase 1· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083· Phase 3· Stichting European Myeloma Network· Source
Recruiting
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT04991948· Phase 1· Celyad Oncology SA· Source
Contact: Kim Dae Won, MD
Active, not recruiting
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
NCT02735083· Phase 1· Institut de Recherches Internationales Servier· Source
Active, not recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591· Phase 3· CG Oncology, Inc.· Source
Recruiting
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
NCT04317534· Phase 2· Greg Durm, MD· Source
Contact: Mari Hardy
Active, not recruiting
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701· Phase 1· Daiichi Sankyo· Source
Recruiting
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
NCT03692429· Phase 1· Celyad Oncology SA· Source
Contact: Kim Dae Won, MD
Recruiting
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839· Phase 1· Institut de Recherches Internationales Servier· Source
Contact: Institut de Recherches Internationales Servier Clinical Studies Department
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error